The disclosure relates to a transcutaneous pharmaceutical composition of monophasic hydroalcoholic type comprising: more than 30% of one or more short chain (C1-C4) alcohols, a steroidal hormone (such as testosterone), at least one fatty acid ester and propylene glycol as a penetration agent, wherein the concentration of said fatty acid ester and propylene glycol as penetration agent with a concentration of from 0.5% to 10% (m/m) of the composition, and an apolar solvent (such as N,N-di-ethyl-m-toluamide, commonly referred as DEET) soluble in the hydroalcoholic phase.
